Literature DB >> 10749871

Crystal structure of a conformation-selective casein kinase-1 inhibitor.

N Mashhoon1, A J DeMaggio, V Tereshko, S C Bergmeier, M Egli, M F Hoekstra, J Kuret.   

Abstract

Members of the casein kinase-1 family of protein kinases play an essential role in cell regulation and disease pathogenesis. Unlike most protein kinases, they appear to function as constitutively active enzymes. As a result, selective pharmacological inhibitors can play an important role in dissection of casein kinase-1-dependent processes. To address this need, new small molecule inhibitors of casein kinase-1 acting through ATP-competitive and ATP-noncompetitive mechanisms were isolated on the basis of in vitro screening. Here we report the crystal structure of 3-[(2,4,6-trimethoxyphenyl) methylidenyl]-indolin-2-one (IC261), an ATP-competitive inhibitor with differential activity among casein kinase-1 isoforms, in complex with the catalytic domain of fission yeast casein kinase-1 refined to a crystallographic R-factor of 22.4% at 2.8 A resolution. The structure reveals that IC261 stabilizes casein kinase-1 in a conformation midway between nucleotide substrate liganded and nonliganded conformations. We propose that adoption of this conformation by casein kinase-1 family members stabilizes a delocalized network of side chain interactions and results in a decreased dissociation rate of inhibitor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10749871     DOI: 10.1074/jbc.M001713200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  Casein kinase I regulates membrane binding by ARF GAP1.

Authors:  Sidney Yu; Michael G Roth
Journal:  Mol Biol Cell       Date:  2002-08       Impact factor: 4.138

2.  Circadian metabolic regulation through crosstalk between casein kinase 1δ and transcriptional coactivator PGC-1α.

Authors:  Siming Li; Xiao-Wei Chen; Lei Yu; Alan R Saltiel; Jiandie D Lin
Journal:  Mol Endocrinol       Date:  2011-11-03

3.  Phosphorylation of CK1delta: identification of Ser370 as the major phosphorylation site targeted by PKA in vitro and in vivo.

Authors:  Georgios Giamas; Heidrun Hirner; Levani Shoshiashvili; Arnhild Grothey; Susanne Gessert; Michael Kühl; Doris Henne-Bruns; Constantinos E Vorgias; Uwe Knippschild
Journal:  Biochem J       Date:  2007-09-15       Impact factor: 3.857

4.  The multiple roles of computational chemistry in fragment-based drug design.

Authors:  Richard Law; Oliver Barker; John J Barker; Thomas Hesterkamp; Robert Godemann; Ole Andersen; Tara Fryatt; Steve Courtney; Dave Hallett; Mark Whittaker
Journal:  J Comput Aided Mol Des       Date:  2009-06-17       Impact factor: 3.686

5.  From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity.

Authors:  Emilie Durieu; Eric Prina; Olivier Leclercq; Nassima Oumata; Nicolas Gaboriaud-Kolar; Konstantina Vougogiannopoulou; Nathalie Aulner; Audrey Defontaine; Joo Hwan No; Sandrine Ruchaud; Alexios-Leandros Skaltsounis; Hervé Galons; Gerald F Späth; Laurent Meijer; Najma Rachidi
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

6.  The kinase CK1ɛ controls the antiviral immune response by phosphorylating the signaling adaptor TRAF3.

Authors:  Yilong Zhou; Chenxi He; Dapeng Yan; Feng Liu; Haipeng Liu; Jianxia Chen; Ting Cao; Mianyong Zuo; Peng Wang; Yan Ge; Haojie Lu; Qinghe Tong; Chengfeng Qin; Yongqiang Deng; Baoxue Ge
Journal:  Nat Immunol       Date:  2016-02-29       Impact factor: 25.606

7.  Functional genomics identifies therapeutic targets for MYC-driven cancer.

Authors:  Masafumi Toyoshima; Heather L Howie; Maki Imakura; Ryan M Walsh; James E Annis; Aaron N Chang; Jason Frazier; B Nelson Chau; Andrey Loboda; Peter S Linsley; Michele A Cleary; Julie R Park; Carla Grandori
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-23       Impact factor: 11.205

Review 8.  Structure, regulation, and (patho-)physiological functions of the stress-induced protein kinase CK1 delta (CSNK1D).

Authors:  Pengfei Xu; Chiara Ianes; Fabian Gärtner; Congxing Liu; Timo Burster; Vasiliy Bakulev; Najma Rachidi; Uwe Knippschild; Joachim Bischof
Journal:  Gene       Date:  2019-07-31       Impact factor: 3.688

9.  CK1epsilon is required for breast cancers dependent on beta-catenin activity.

Authors:  So Young Kim; Ian F Dunn; Ron Firestein; Piyush Gupta; Leslie Wardwell; Kara Repich; Anna C Schinzel; Ben Wittner; Serena J Silver; David E Root; Jesse S Boehm; Sridhar Ramaswamy; Eric S Lander; William C Hahn
Journal:  PLoS One       Date:  2010-02-01       Impact factor: 3.240

10.  Breast cancer-specific mutations in CK1epsilon inhibit Wnt/beta-catenin and activate the Wnt/Rac1/JNK and NFAT pathways to decrease cell adhesion and promote cell migration.

Authors:  Silvie Foldynová-Trantírková; Petra Sekyrová; Katerina Tmejová; Eva Brumovská; Ondrej Bernatík; Wulf Blankenfeldt; Pavel Krejcí; Alois Kozubík; Tomás Dolezal; Lukás Trantírek; Vítezslav Bryja
Journal:  Breast Cancer Res       Date:  2010-05-27       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.